Provided by Tiger Fintech (Singapore) Pte. Ltd.

Revelation Biosciences, Inc.

2.63
-0.0700-2.59%
Post-market: 2.52-0.1100-4.18%18:53 EDT
Volume:16.04K
Turnover:42.15K
Market Cap:2.38M
PE:-0.02
High:2.80
Open:2.66
Low:2.51
Close:2.70
Loading ...

Top Premarket Decliners

MT Newswires Live
·
17 Mar

REVB Announces Positive Test Results

Zacks Small Cap Research
·
17 Mar

BRIEF-Gemini Priming Attenuates Inflammation In Human Peripheral Blood Mononuclear Cells

Reuters
·
17 Mar

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

THOMSON REUTERS
·
17 Mar

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

Business Wire
·
17 Mar

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

Business Wire
·
13 Mar

REVB Starts 2025 With Bright Future Ahead

Zacks Small Cap Research
·
07 Mar

Revelation Biosciences Q4 EPS $(4.98)

Benzinga
·
07 Mar

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

Business Wire
·
07 Mar

BUZZ-Stephens lowers PT for Addus HomeCare amid Medicaid funding uncertainity

Reuters
·
26 Feb

BRIEF-Revelation Biosciences Doses First Patient In Prime Phase 1B Clinical Study Of Gemini In CKD Patients

Reuters
·
26 Feb

Revelation doses first patient in PRIME Phase 1b clinical study

TIPRANKS
·
26 Feb

Revelation Biosciences Doses First Patient in Prime Phase 1B Clinical Study of Gemini in Ckd Patients

THOMSON REUTERS
·
26 Feb

Revelation Biosciences Inc - Top-Line Data Expected by Mid-Year

THOMSON REUTERS
·
26 Feb

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Business Wire
·
26 Feb

BRIEF-Revelation Biosciences Says Regained Compliance With Nasdaq Minimum Bid Price Requirement

Reuters
·
25 Feb